Logo image
Back
The clinical electrophysiology of intravenous indecainide
Journal article   Peer reviewed

The clinical electrophysiology of intravenous indecainide

Leonard N. Horowitz, Scott R. Spielman, Charles R. Webb, Joel Morganroth and Allan M. Greenspan
The American heart journal, v 110(4), pp 784-788
1985
DOI: https://doi.org/10.1016/0002-8703(85)90457-0
PMID: 4050649
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

The electrophysiologic effects of indecainide, a new class IC antiarrhythmic agent, were assessed in 10 patients with left ventricular dysfunction and inducible sustained ventricular tachycardia. Indecainide was administered intravenously in a dose of 60 to 90 mg/kg at a rate of 12.5 to 15 μg/kg/min. Indecainide had no effect on sinus node function or atrial and ventricular effective refractory periods. The AH (106 ± 13 vs 130 ± 24 msec, p <0.002) and HV (57 ± 7 vs 73 ± 19 msec, p <0.001) intervals were significantly increased. The QRS duration increased (102 ± 9 vs 120 ± 13 msec, p<0.001); however, the JT duration did not change. Induction of ventricular tachycardia was prevented in 1 of 10 patients. In the remaining nine patients, the ventricular tachycardia cycle length was significantly prolonged (248 ± 47 vs 320 ± 71 msec, p <0.001). Indecainide significantly depressed intracardiac conduction at several sites.

Metrics

4 Record Views
12 citations in Web of Science
14 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Cardiac & Cardiovascular Systems
Logo image